‫CDF نے ترقیاتی ثقافتی شعبے میں اپنے کردار کو اجاگر کرتے ہوئے FII ریاض فورم میں اپنی شرکت کو انجام تک پہنچا دیا

FII انسی ٹیوٹ کے تزویراتی شراکت دار کے طور پر ریاض، سعودی عرب، 28 اکتوبر 2022 /PRNewswire/ — ثقافتی ترقیاتی فنڈ (CDF) نے مستقبل کی سرمایہ کاری کی پیش قدمی (FII) فورم میں اپنی شرکت کو کامیابی کے ساتھ انجام تک پہنچا دیا ہے، جو مملکت سعودیہ کے وزیر اعظم جناب عزت مآب ولی عہد […]

FII انسی ٹیوٹ کے تزویراتی شراکت دار کے طور پر

ریاض، سعودی عرب، 28 اکتوبر 2022 /PRNewswire/ — ثقافتی ترقیاتی فنڈ (CDF) نے مستقبل کی سرمایہ کاری کی پیش قدمی (FII) فورم میں اپنی شرکت کو کامیابی کے ساتھ انجام تک پہنچا دیا ہے، جو مملکت سعودیہ کے وزیر اعظم جناب عزت مآب ولی عہد شہزادہ محمد بن سلمان بن عبد العزیر کی زیر سرپرستی جمعرات کو ریاض میں اختتام پذیر ہوا ہے۔ 

عالمی رہنماؤں، ممتاز کاروباری شخصیات اور سرکردہ عالمی فنڈ مینیجرز نے FII فورم میں شرکت کی، جو اب چھٹے ایڈیشن میں ہے۔ CDF نے اس فورم کا اہتممام کرنے والے ادارے کے تزویراتی شراکت دار کے طور پر کام کیا۔ یہ فورم اقتصادی ترقی کو فروغ دینے کے لیے دستیاب سرمایہ کاری کے مواقع سے مستفید ہونے، جدت پسندی کو تقویت دینے، اعلی ٹیکنالوجی کو استعمال میں لانے اور عالمی چیلنجوں پر قابو پانے کے مقصد کے ساتھ 25 – 27 اکتوبر کو شاہ عبد العزیز بین الاقوامی کانفرنس سینٹر میں منعقد ہوا۔

ایک پینل مباحثے کے دوران، جس کا عنوان “اگلی تخلیق کار معیشت” تھا، CDF کے چیف ایگزیکٹیو آفیسر محمد بندیال نے تبادلہ خیال کیا کہ کس طرح جدید ٹیکنالوجی اور نیا میڈیا ثقافت کی شکل کو تبدیل کر رہے ہیں اور ایسے رجحانات کو فروغ دینے میں مدد دے رہے ہیں جو موسیقی اور فلم سمیت ثقافتی وضعوں کے لیے حیرت انگیز مواقع پیدا کر رہے ہیں۔

جناب بندیال نے ثقافتی تخلیق کاروں اور ان کے ناظرین کے بیچ رکاوٹوں میں کمی لانے، شعبے کو ترقی دینے کے لیے سود مندی کے نئے ذرائع پیدا کرنے اور مملکت کی معیشت میں اس کے کردار کو مضبوط بنانے میں ان جدتوں کے کردار کا خلاصہ پیش کیا۔ انہوں نے تخلیق کار معیشت کی تیز رفتار ترقی کو بھی اجاگر کیا اور یہ کہ یہ ثقافت کے ہر پہلو میں کیسے تخلیق کاروں اور سرمایہ کاروں کو مدد دے رہی ہے۔

“فلم اہلکار – علاقائی فلمی صنعت کو ترقی دینا” کے عنوان کے ایک تصوراتی مکالمے میں، CDF فلم سیکٹر فنانسنگ پروگرام کے ڈائریکٹر فیصل الحصیری نے صنعت کی سرمایہ کاری کو راغب کرنے کی طاقت، سیاحتی مقامات کو فروغ دینے اور کسی ملک کے منفرد فنون اور ثقافتی منظرنامے کو نمایاں کرنے کا حوالہ دیتے ہوئے کسی ملک کی معیشت کی ترقی میں فلم سازی کی اہمیت کو اجاگر کیا ہے۔

جناب الحصیری نے فلم سازی کے لیے فنڈ فراہم کرنے میں سرکاری-نجی اشتراک عمل کی اہمیت پر زور دیا۔ انہوں تبصرہ کیا کہ اس باہمی تعاون کے ذریعے، مقامی فلمساز فلمی سیٹ بنانے اور قومی اور عالمی فلمی پروڈکشن کے لیے فلم بندی کے مقامات تیار کرنے کے لیے درکار صحیح وسائل تک رسائی حاصل کر سکتے ہیں۔

FII فورم میں CDF کا پیولین ثقافت میں سرمایہ کاری کی اہمیت اور یہ کہ یہ اقتصادی ترقی کو تیز کرنے میں کیسے مدد دے سکتی ہے پر عوامی مکالمے کے لئے کھلا تھا۔ پیولین نے مستحکم مالیاتی ذرائع فراہم کرنے کے مقصد کے لیے قائم مختلف CDF پروگراموں کے بارے میں ناظرین کو آگاہ بھی کیا۔

FII فورم میں اپنی پوری موجودگی کے دوران، CDF نے اقتصادی ترقی میں اپنے کردار کے بارے میں آگاہی پیدا کرنے، نجی اور غیر منافع بخش اداروں کو ثقافتی ماحولی نظام میں مستحکم ترقی پیدا کرنے کی ترغیب دینے کے علاوہ ثقافتی شعبے کی ترقی کرنے کے وسیع امکان کو اجاگر کر کے اس شعبے میں سرمایہ کاری راغب کرنے اور مالیاتی اداروں کو اس میں سرمایہ کاری کرنے کی حوصلہ افزائی کرنے کی بھرپور کوشش کی۔

یہ کاوشیں FII کے ادارے کے مقاصد کے ساتھ ہم آہنگ ہیں جو کہ عالمی کھلاڑیوں کا ایک مؤثر نیٹ ورک بنانے کے علاوہ ابھرتے ہوئے شعبوں پر روشنی ڈالتا ہے جن سے آنے والی دہائیوں میں بین الاقوامی سرمایہ اور عالمی معیشت کے مستقبل کو تشکیل دینے کی توقع ہے۔

تصویر – https://mma.prnewswire.com/media/1932762/CDF_Mohammed_Bindayel.jpg
Photo – https://mma.prnewswire.com/media/1932763/Cultural_Development_Fund.jpg

EMGA Secures US$ 20M Debt Finance for Costa Rica’s Banco Improsa

LONDON, Oct. 31, 2022 (GLOBE NEWSWIRE) — Emerging Markets Global Advisory LLP (EMGA) for the second time working with Banco Improsa, secures this US$20M facility from the Spanish Agency for International Development Cooperation (AECID) – AECID (advised by COFIDES). Commenting on the transaction, Felix Alpizar, General Manager of BANCO IMPROSA, said: “Banco Improsa is very honored to be […]

LONDON, Oct. 31, 2022 (GLOBE NEWSWIRE) — Emerging Markets Global Advisory LLP (EMGA) for the second time working with Banco Improsa, secures this US$20M facility from the Spanish Agency for International Development Cooperation (AECID) – AECID (advised by COFIDES).

Commenting on the transaction, Felix Alpizar, General Manager of BANCO IMPROSA, said: “Banco Improsa is very honored to be recognized by AECID and COFIDES for both its track record and programs to finance and support Costa Rican micro, small and medium-sized enterprises (MSMEs). With this credit we will continue our contribution to the economic and social development of the country.”

EMGA’s Head of Investment Banking Sajeev Chakkalakal said, “A pleasure again to facilitate Banco Improsa’s continued vision of supporting SMEs within Costa Rica and complete this funding solution with AECID (advised by COFIDES).”

José Luis Curbelo, chairman and CEO of COFIDES, stated that “we are pleased to support AECID in its first impact project with EMGA and IMPROSA in the Central American region. The transaction will be used to finance small and medium enterprises in Costa Rica, which will contribute to the creation and maintenance of quality jobs and reducing inequalities. We look forward to continuing these strategic partnerships, which enhance economic growth in developing countries by strengthening the private sector through sound financial support.”

Carlos Jiménez Aguirre, General Manager of FONPRODE and Head AECID’s Financial Cooperation Department expressed that “the formalization of this transaction reflects Spanish Cooperation’s aims to contribute to expand the financial support for Costa Rican micro, small and medium-sized enterprises (MSMEs), as MSMEs play a key role in creating and maintaining decent jobs and reducing inequalities. Our intention is to expand this kind of support to other Central American countries in providing access to finance to MSMEs, with a special focus on mainstreaming gender and climate change strategies in private sector activities.”

Emerging Markets Global Advisory LLP, based in London, helps emerging market based financial institutions and corporates seeking new debt or equity capital.

Banco Improsa was founded in 1995 and is a niche bank with a specialization in providing financial solutions and services to MSMEs, which account for most of its portfolio. It has an extensive track record in providing support and advisory services to MSMEs. Banco Improsa’s key success factor lies in its commitment to high standards of personalized, agile, and flexible service, which, together with customized financial solutions, have enabled it to achieve a solid position in these segments. Banco Improsa is part of Grupo Financiero Improsa (GFI).

Fund for the Promotion of Development (FONPRODE), managed by Spanish Agency for International Development Cooperation (AECID) with the support of COFIDES (Spanish Development Finance Institution). AECID is the main management body of Spanish Cooperation and is oriented towards the fight against poverty and the promotion of sustainable development. COFIDES provides support management for FONPRODE with reimbursable financing operations that promote social and economic development of partner countries through investments or transfers of economic resources with a reimbursable nature. FONPRODE may finance non-reimbursable and reimbursable debt and equity. Examples of refundable financing offered by FONPRODE are loans to financial service providers aimed at financial inclusion.

COFIDES, a state-owned company engaging in the management of State and third-party as well as its own funds, pursues several aims; internationalization of Spain’s economy, furtherance of economic development and fortification of the solvency of companies affected by COVID-19. In addition to the Spanish State, its shareholders include Banco Santander, Banco Bilbao Vizcaya Argentaria (BBVA), Banco Sabadell and Development Bank of Latin America (CAF).

Jeremy Dobson

info@emergingmarketsglobaladvisory.com

GlobeNewswire Distribution ID 1000753987

Conagen’s fermentation platform expands on promising novel forms of vitamin K2

Bedford, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) — Biotech innovator, Conagen announced the development of its fermentation-derived vitamin K2 – a high-purity all-trans menaquinone-7 (MK-7).  This is the first molecule from a proprietary platform for producing novel, pure, long-chain menaquinone forms of the vitamin. The platform enables low-cost manufacturing and yields high-quality products, making it […]

Bedford, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) — Biotech innovator, Conagen announced the development of its fermentation-derived vitamin K2 – a high-purity all-trans menaquinone-7 (MK-7).  This is the first molecule from a proprietary platform for producing novel, pure, long-chain menaquinone forms of the vitamin. The platform enables low-cost manufacturing and yields high-quality products, making it attractive to health brands.

“Conagen’s MK-7 technology produces a clean profile of the vitamin without other similar molecules, such as ubiquinone,” said Casey Lippmeier, Ph.D., senior vice president of innovation at Conagen. “Our process allows us to make pure forms of any long-chain menaquinone, be it 6, 7, 8, 9, and these can be consumed in various combinations with other vitamins or with each other to make the most effective supplement possible. As the clinical evidence evolves, so can the supplement.”

Vitamin K2 helps to regulate calcium mobility in bones and restricts calcium buildup in blood vessels, leading to stroke and heart disease. MK-7 is the more bioavailable form of K2 on the market; the other major form is MK-4, which both have taken a strong position in the markets for bone and cardiovascular health.

The biological activity of MK-7 is strictly linked to its all-trans configuration, which is naturally found in fermented superfoods such as natto. Cis-analogues are considered biologically inactive. Synthetic versions of MK-7 contain some amount of the cis-isomer form. Low-quality sources containing cis forms affect the efficacy of the vitamin.

Other long-chain forms of vitamin K2, such as MK-8 and MK-9, exist naturally in cheeses. Research on the health benefits of these other K2 forms has only begun to emerge.

Personalized nutrition is popular with consumers looking for technological breakthroughs in functional foods and nutrition. Conagen’s cost-effective fermentation-derived MK-7 provides new opportunities for brands to develop products to meet the demand of the growing aging population.

“We’re demonstrating our capabilities with innovative technologies that expand market choices in nutrition,” said Lippmeier. “Our fermentation and bioconversion platforms have also produced the clean nutrient ergothioneine and the antioxidant taxifolin, further demonstrating the versatility of our platform technologies.”

Conagen’s research into the MK-7 production process was done in part as a 3-year collaboration with the lab of Prof. Anthony Sinskey at the Massachusetts Institute of Technology.

Health brands interested in non-GMO, vegan vitamin K2 MK-4 and MK-7 and special ingredients, such as ErgoActive® L-Ergothioneine® and Taxifolin BC DHQ® for nutrition and food and beverage preservation, respectively, can contact Blue California, a pipeline partner of Conagen. To inquire more about Conagen’s products or partnerships, please visit www.conagen.com.

About Conagen

Conagen is a product-focused, synthetic biology R&D company with large-scale manufacturing service capabilities. Our scientists and engineers use the latest synthetic biology tools to develop high-quality, sustainable, nature-based products by precision fermentation and enzymatic bioconversion. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries.

Attachments

Ana Arakelian, Head of Public Relations and Communications
Conagen
+1.949.750.6812
ana.arakelian@conagen.com

GlobeNewswire Distribution ID 8685378

Dominica’s Anichi Resort & Spa provides a 2% annual return while under construction

Roseau, Oct. 31, 2022 (GLOBE NEWSWIRE) — Anichi Resort & Spa will be providing a 2% annual return to investors despite being under construction. The management of the much-anticipated five-star luxury resort and spa in Dominica has said that the project is in full swing, and that once construction is completed, annual returns will be […]

Roseau, Oct. 31, 2022 (GLOBE NEWSWIRE) — Anichi Resort & Spa will be providing a 2% annual return to investors despite being under construction. The management of the much-anticipated five-star luxury resort and spa in Dominica has said that the project is in full swing, and that once construction is completed, annual returns will be based on the resort’s operation.

Following an official update, an estimated 70% of the project is now complete; this includes the flooring as well as an extensive electricity infrastructure. The resort is being built on 12 acres of land, with 128 rooms. I will host world-class amenities, such as a lagoon swimming pool, an infinity pool, restaurants, a business centre and many others. Overlooking a picturesque beach, the resort will tastefully blend its modern architecture with the landscape’s tropical foliage.

Developed by Oriental Developers (Caribbean) Ltd, the resort will form part of the Autograph Collection, a premium international brand developed by renowned hotelier Marriott International. This links the resort to more than 100 luxury lifestyle hotels across 30 countries and territories – all of which have been constructed as part of Autograph Collection Hotels. Furthermore, Anichi Resort will be managed by Highgate, a dominant player in major US gateway cities with a growing footprint in the Caribbean and Latin America.

Anichi Resort & Spa is also one of the premium real estate options approved by the Dominican government’s Citizenship by Investment (CBI) programme. The CBI Index of 2022, published by the PWM Magazine of the Financial Times, recognises it as the “World’s Best Citizenship by Investment Programme”. The minimum investment threshold for Anichi Resort & Spa is $220,000 (USD), an expenditure which also comes with lifetime Dominican citizenship and property ownership.

The resort will bolster the tourism sector and generate extensive employment for locals. The country already occupies a notable position, ranking first among 25 other Caribbean islands – winning due to its lush green jungles, hot springs and striking black-sand beaches. Annually, scores of investors fly to Dominica owing to its large number of government-approved investment projects. The Citizenship by Investment Programme of Dominica allows these individuals to purchase freehold shares in government-approved properties.

Anichi Resort & Spa provides investors and CBI applicants with a Return on Investment (ROI) as well as a route towards diversifying their portfolios and planning their wealth

The Prime Minister of Dominica, Dr Roosevelt Skerrit, praised the CBI Programme, “Thanks to the real-estate investment option of the Citizenship by Investment Programme,” he noted, “the country is catching the attraction of travel-enthusiasts and is now known for [its] luxury tourism offering. Under the Citizenship Programme, investors looking to expand their real estate portfolio have the opportunity to invest in established luxury hotel brands and villas.” 

Dominica’s real estate investment option has long provided premium, luxury projects for investment. A prior example of this is Secret Bay, a real estate property which paid out more than $1 million (USD) in returns to investors. The Residences at Secret Bay also promises great returns, having drawn more than 100 Citizenship by Investment (CBI) owners. The resort has already won a number of awards, and it is anticipated that Anichi Resort & Spa will likewise be counted as one of the jewels in Dominica’s real estate crown.

Anichi Resort promises to be a meaningful asset during this time of global uncertainty. CS Global Partners, a legal consulting firm working in the investment citizenship field, noted that, beyond the resort’s world-class architecture and lush surrounding environment, “[t]he project also brings in interest from investors keen to participate in the development through Dominica’s Citizenship by Investment (CBI) Programme. Once completed, the resort promises to transform Dominica’s tourism sector while also boosting employment for the local community”.

Concurrently, Dominica is witnessing the construction of several other hotels, including a Hilton hotel, which will also fall under the government-approved real estate investment options of the country’s CBI programme. Many of these properties are being built to be sustainable and climate-resilient, with the continued construction of such resorts and hotels positioning the island as a top destination for eco-luxury resorts.

Dominica’s real estate is thus proving to be a popular option among investors and high net-worth individuals (HNWIs). Bolstering investment is the strength of the country’s CBI programme. The credibility and trustworthiness of Dominica’s programme has been maintained since its launch almost three decades ago, and it has been ranked the world’s best CBI programme for its sixth consecutive year. Alongside alternative citizenship, the Citizenship by Investment Programme of Dominica provides a number of other opportunities to investors. These include:

  • The ability to become a global citizen and be part of a global community transcends Dominica’s land borders.
  • The ability to hold multiple citizenships.
  • A citizenship that is granted for life and can be passed on to future generations.
  • An opportunity to provide families and children with a peaceful, stable, safe and welcoming home.
  • Access to countless business opportunities, with the option of portfolio diversification.
  • Enhanced opportunities for wealth planning and expanding business overseas.
  • A stable currency, with Dominica’s currency, the East Caribbean Dollar (XCD), pegged to USD.

These factors, combined with alternative citizenship, present individuals with a rich array of business and personal advantages. As the success and promise of the Anichi Resort & Spa attest, the island along with its CBI programme offers investment with unrivalled returns.

PR Dominica
Commonwealth of Dominica
001 (767) 266 3919
mildred.thabane@csglobalpartners.com
.

GlobeNewswire Distribution ID 8685334

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rite Aid Corporation Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – RAD

NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Rite Aid Corporation (NYSE: RAD) between April 14, 2022 and September 28, 2022, both dates inclusive (the “Class Period”). A class […]

NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Rite Aid Corporation (NYSE: RAD) between April 14, 2022 and September 28, 2022, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 19, 2022.

SO WHAT: If you purchased Rite Aid securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Rite Aid class action, go to https://rosenlegal.com/submit-form/?case_id=9388 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 19, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) despite representations to the contrary, the number of new members (i.e., “lives”) that Elixir’s (a subsidiary of the Company) pharmacy benefit management (“PBM”) services business was adding during the selling season ending on January 1, 2023 was in material decline; (2) Rite Aid was likely to recognize a significant charge for the impairment of goodwill related to Elixir due to a decrease in “lives” covered by Elixir’s PBM services business; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Rite Aid class action, go to https://rosenlegal.com/submit-form/?case_id=9388 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8684860

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Opendoor Technologies Inc. f/k/a Social Capital Hedosophia Holdings Corp. II Investors to Secure Counsel Before Important Deadline in Securities Class Action – OPEN

NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers and acquirers of the securities of Opendoor Technologies Inc. f/k/a Social Capital Hedosophia Holdings Corp. II (NASDAQ: OPEN): (i) between December 21, 2020 and September 16, 2022, both dates inclusive (the “Class Period”); and/or (ii) […]

NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers and acquirers of the securities of Opendoor Technologies Inc. f/k/a Social Capital Hedosophia Holdings Corp. II (NASDAQ: OPEN): (i) between December 21, 2020 and September 16, 2022, both dates inclusive (the “Class Period”); and/or (ii) pursuant and/or traceable to the offering documents issued in connection with the business combination between the Social Capital Hedosophia Holdings Corp. II and Opendoor Labs Inc. completed on or about December 18, 2020 (the “Merger”) of the important December 6, 2022 lead plaintiff deadline.

SO WHAT: If you acquired Opendoor securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Opendoor class action, go to https://rosenlegal.com/submit-form/?case_id=9133 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 6, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the offering documents for the Merger were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, according to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the offering documents and defendants made false and/or misleading statements and/or failed to disclose that: (1) the algorithm (“Algorithm”) Opendoor used to make offers for homes could not accurately adjust to changing house prices across different market conditions and economic cycles; (2) as a result, Opendoor was at an increased risk of sustaining significant and repeated losses due to residential real estate pricing fluctuations; (3) accordingly, defendants overstated the purported benefits and competitive advantages of the Algorithm; and (4) as a result, the offering documents and defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Opendoor class action, go to https://rosenlegal.com/submit-form/?case_id=9133 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8684916

ABT IMPORTANT DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Abbott Laboratories Investors to Secure Counsel Before Important October 31 Deadline in Securities Class Action – ABT

NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the “Class Period”), of the important October 31, 2022 lead plaintiff deadline. SO WHAT: If you […]

NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the “Class Period”), of the important October 31, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Abbott securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Abbott class action, go to https://rosenlegal.com/submit-form/?case_id=8453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 31, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) according to the U.S. Food and Drug Administration (“FDA”), Abbott had “egregiously unsanitary” conditions at its Sturgis, Michigan facility which produced nearing half of Abbott’s various forms of infant formula under the brands Similac, Alimentum, and EleCare; (2) as a result, Abbott’s infant formula business was in dire jeopardy given the flagrant violations of federal and state health and safety regulations; (3) based on inspections by the FDA between 2019 and 2022, Abbott failed to establish process controls “designed to ensure that infant formula does not become adulterated due to the presence of microorganisms in the formula or in the processing environment” and Abbott also failed to “ensure that all surfaces that contacted infant formula were maintained to protect infant formula from being contaminated by any source”; (4) the unhygienic conditions of the Sturgis facility resulted in the recall of Abbott’s infant formula and closure of the Sturgis facility; and (5) as a result, defendants’ public statements about Abbott’s business, operations, and prospects were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Abbott class action, go to https://rosenlegal.com/submit-form/?case_id=8453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8685210

ROSEN, LEADING INVESTOR COUNSEL, Encourages Argo Group International Holdings, Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ARGO

NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Argo Group International Holdings, Ltd. (NYSE: ARGO) between February 13, 2018 and August 9, 2022, both dates inclusive (the “Class Period”), of the important December 20, 2022 lead plaintiff deadline. SO WHAT: […]

NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Argo Group International Holdings, Ltd. (NYSE: ARGO) between February 13, 2018 and August 9, 2022, both dates inclusive (the “Class Period”), of the important December 20, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Argo Group securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Argo Group class action, go to https://rosenlegal.com/submit-form/?case_id=9346 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 20, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements regarding the Company’s: (1) ability to set appropriate reserves; (2) changing of its underwriting policies; and (3) writing of policies outside of its “core” business. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Argo Group class action, go to https://rosenlegal.com/submit-form/?case_id=9346 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8685209

MDT INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Medtronic plc Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action – MDT

NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Medtronic plc (NYSE: MDT) between June 8, 2019 and May 25, 2022, both dates inclusive (the “Class Period”), of the important November 7, 2022 lead plaintiff deadline. SO WHAT: If you […]

NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Medtronic plc (NYSE: MDT) between June 8, 2019 and May 25, 2022, both dates inclusive (the “Class Period”), of the important November 7, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Medtronic securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Medtronic class action, go to https://rosenlegal.com/submit-form/?case_id=8603 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 7, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Medtronic’s product quality control systems were inadequate; (2) Medtronic had failed to comply with numerous regulations regarding risk assessment, corrective and preventive action, complaint handling, device recalls, and reporting of adverse events; (3) these failures increased the risk of regulatory investigation and action; (4) as a result of Medtronic’s misconduct, the U.S. Food and Drug Administration (“FDA”) would delay the approval of additional Medtronic MiniMed devices, including the MiniMed 780G; (5) these delays in product approvals, as well as the Company’s need to improve its quality control systems, would negatively affect Medtronic’s financial performance and cause it to fall further behind its competitors; and (6) as a result of the foregoing, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Medtronic class action, go to https://rosenlegal.com/submit-form/?case_id=8603 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8684906